A 2023 position statement from the Endocrine Society on GLP-1 receptor agonist therapy notes that "dose escalation intervals shorter than 4 weeks are associated with higher rates of treatment discontinuation and should be avoided in routine clinical practice." [11] That statement aligns with what SUSTAIN-7 and post-market real-world analyses have shown
Its a groundbreaking alternative for patients who find injections challenging or inconvenient
Our clinic is in Southlake, TX and proudly serves patients from Dallas, Fort Worth, Southlake, Aledo, Keller, Frisco, Grapevine, Colleyville, Arlington, Alliance, Coppell, and neighboring areas
Caspase-mediated death pathways show reduced activation[6][8]